Anthera Pharmaceuticals Inc  

(Public, NASDAQ:ANTH)   Watch this stock  
Find more results for Debra Adams�
2.89
-0.05 (-1.70%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.84 - 2.97
52 week 2.63 - 5.04
Open 2.97
Vol / Avg. 63,826.00/121,236.00
Mkt cap 57.87M
P/E     -
Div/yield     -
EPS -10.18
Shares 20.02M
Beta 1.46
Inst. own 67%
May 12, 2014
Q1 2014 ANTHERA PHARMACEUTICALS INC Earnings Release (Estimated) Add to calendar
Mar 12, 2014
Q4 2013 ANTHERA PHARMACEUTICALS INC Earnings Release
Mar 5, 2014
ANTHERA PHARMACEUTICALS INC at Cowen Health Care Conference (Breakout Session)
Mar 5, 2014
ANTHERA PHARMACEUTICALS INC at Cowen Health Care Conference
Feb 24, 2014
ANTHERA PHARMACEUTICALS INC at Citi Global Healthcare Conference
Feb 13, 2014
ANTHERA PHARMACEUTICALS INC at Leerink Swann Global Healthcare Conference
Feb 10, 2014
ANTHERA PHARMACEUTICALS INC at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets - -
Return on average equity - -
Employees 23 -
CDP Score - -

Address

Suite B, 25801 Industrial Blvd
HAYWARD, CA 94545
United States - Map
+1-510-8565600 (Phone)
+1-510-8565597 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products to treat serious diseases associated with autoimmune disorders, including lupus, glomerulonephritis and IgA nephropathy. The Company�s primary product candidate, blisibimod, targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. It is advancing its development of blisibimod, an inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. It owns worldwide rights to blisibimod in all potential indications.

Officers and directors

Christopher S. Henney Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Paul F. Truex President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
May Liu Senior Vice President - Finance and Administration, Principal Accounting Officer
Age: 37
Bio & Compensation  - Reuters
Debra Odink Ph.D. Senior Vice President, Chief Technology Officer
Age: 49
Bio & Compensation  - Reuters
Paula Adams Ph.D. Senior Vice President - Global Regulatory Affairs and Compliance
Age: 50
Bio & Compensation  - Reuters
Colin Hislop M.D. Senior Vice President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Steven B. Engle Director
Bio & Compensation  - Reuters
Bogdan Dziurzynski Independent Director
Age: 64
Bio & Compensation  - Reuters
Daniel K. Spiegelman Independent Director
Age: 54
Bio & Compensation  - Reuters
David E. Thompson Independent Director
Age: 65
Bio & Compensation  - Reuters